Your browser is no longer supported. Please, upgrade your browser.
XOMA XOMA Corporation daily Stock Chart
XOMA Corporation
Index- P/E- EPS (ttm)-0.93 Insider Own9.60% Shs Outstand8.57M Perf Week5.42%
Market Cap156.57M Forward P/E- EPS next Y-1.43 Insider Trans3.49% Shs Float8.12M Perf Month7.03%
Income-7.70M PEG- EPS next Q-0.55 Inst Own52.60% Short Float13.39% Perf Quarter38.30%
Sales13.00M P/S12.04 EPS this Y-318.90% Inst Trans-1.91% Short Ratio13.18 Perf Half Y28.93%
Book/sh2.76 P/B6.62 EPS next Y-31.20% ROA-13.50% Target Price27.50 Perf Year-20.63%
Cash/sh5.65 P/C3.23 EPS next 5Y19.00% ROE-62.70% 52W Range11.02 - 25.99 Perf YTD44.43%
Dividend- P/FCF- EPS past 5Y43.80% ROI-40.60% 52W High-29.70% Beta1.27
Dividend %- Quick Ratio7.20 Sales past 5Y-31.60% Gross Margin- 52W Low65.81% ATR1.03
Employees11 Current Ratio7.20 Sales Q/Q1656.20% Oper. Margin-75.20% RSI (14)62.53 Volatility5.15% 6.57%
OptionableNo Debt/Eq0.94 EPS Q/Q145.30% Profit Margin-59.00% Rel Volume0.64 Prev Close18.27
ShortableYes LT Debt/Eq0.87 EarningsAug 05 BMO Payout- Avg Volume82.46K Price18.27
Recom- SMA2011.12% SMA5010.13% SMA20026.01% Volume0 Change0.00%
Jan-18-18Reiterated H.C. Wainwright Buy $38 → $49
Oct-17-17Resumed H.C. Wainwright Buy $38
Sep-05-17Upgrade Wedbush Neutral → Outperform $9 → $19
Jun-12-17Initiated H.C. Wainwright Buy $15
Nov-14-16Downgrade Wedbush Outperform → Neutral $17 → $14
Mar-11-16Reiterated Wedbush Outperform $6 → $3
Jul-23-15Downgrade Jefferies Buy → Hold
Jul-22-15Downgrade Piper Jaffray Overweight → Neutral
Jul-22-15Downgrade Ladenburg Thalmann Buy → Neutral
Oct-10-14Resumed ROTH Capital Buy $9
Apr-29-14Upgrade MLV & Co Hold → Buy $7
Mar-11-14Downgrade MLV & Co Buy → Hold $8 → $7
Mar-05-14Reiterated Ladenburg Thalmann Buy $6.50 → $10
Oct-31-13Reiterated MLV & Co Buy $7.50 → $8
May-09-13Reiterated Ladenburg Thalmann Buy $5 → $6
May-14-12Initiated Cowen & Co Outperform
Mar-31-11Reiterated MLV Capital Buy $12 → $10
Mar-23-11Reiterated RBC Capital Mkts Outperform $8 → $6
Jan-06-11Reiterated Ladenburg Thalmann Buy $12 → $16
Jan-04-11Reiterated Wedbush Outperform $12 → $16
Jul-09-19 02:07PM  What Kind Of Share Price Volatility Should You Expect For XOMA Corporation (NASDAQ:XOMA)? Simply Wall St.
Jun-13-19 06:45AM  First Patient Dosed with Gevokizumab in Collaborator Clinical Study in Metastatic Colorectal Cancer, Gastroesophageal Cancer, and Renal Cell Carcinoma GlobeNewswire
Jun-07-19 09:25AM  If You Had Bought XOMA (NASDAQ:XOMA) Stock Five Years Ago, You'd Be Sitting On A 81% Loss, Today Simply Wall St.
May-06-19 07:55PM  Xoma (XOMA) Surpasses Q1 Earnings and Revenue Estimates Zacks
06:43PM  Xoma: 1Q Earnings Snapshot Associated Press
04:30PM  XOMA Reports First Quarter 2019 Financial Results and Operating Highlights GlobeNewswire
May-01-19 10:33AM  Will Xoma (XOMA) Report Negative Q1 Earnings? What You Should Know Zacks
Apr-12-19 05:20PM  Portland biotech inks $9M+ deal for drug royalties American City Business Journals
Apr-11-19 12:14PM  Is XOMA Corporation's (NASDAQ:XOMA) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Apr-08-19 06:00AM  XOMA Acquires Royalty Rights to Five Hematology Candidates GlobeNewswire
Apr-03-19 07:00AM  XOMA to Present at the 2019 H.C. Wainwright Global Life Sciences Conference GlobeNewswire +6.44%
Mar-07-19 07:05AM  XOMA Reports Fourth Quarter and Full Year 2018 Financial Results and Operating Highlights GlobeNewswire
Mar-05-19 07:00AM  XOMA to Present at the Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Feb-21-19 05:48PM  Stealth rally happening in value stocks, is the trend here to stay CNBC Videos
Feb-13-19 07:00AM  XOMA Receives $5.5 Million Payment from Rezolute GlobeNewswire +13.82%
Feb-04-19 07:28AM  How Much Are XOMA Corporation (NASDAQ:XOMA) Insiders Spending On Buying Shares? Simply Wall St.
Jan-03-19 04:35PM  XOMA Announces Barbara Kosacz Joins its Board of Directors GlobeNewswire
Dec-18-18 04:43PM  XOMA Announces Closing of Rights Offering GlobeNewswire
Nov-19-18 04:30PM  XOMA Announces Commencement of Rights Offering GlobeNewswire
Nov-07-18 11:55AM  Xoma (XOMA) Reports Q3 Loss, Tops Revenue Estimates Zacks +8.35%
10:52AM  Xoma: 3Q Earnings Snapshot Associated Press
07:05AM  XOMA Announces Proposed Rights Offering GlobeNewswire
07:00AM  XOMA Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-30-18 08:05AM  Leading BioSciences Announces Appointments of James R. Neal and James Sapirstein to Board of Directors GlobeNewswire
Oct-29-18 10:31AM  Xoma (XOMA) Q3 Earnings Preview: What's Shaping Up? Zacks
Oct-25-18 08:15AM  Analysis: Positioning to Benefit within Middlesex Water, On Deck Capital, New Relic, Toro, XOMA, and ESCO Technologies Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire -7.49%
Sep-27-18 04:30PM  XOMA to Present at the Cantor Fitzgerald Healthcare Conference 2018 and the 2018 BIO Investor Forum GlobeNewswire -6.07%
Sep-24-18 12:15PM  The XOMA Corporation (NASDAQ:XOMA) Ownership Structure Could Be Important Simply Wall St. +5.68%
Sep-21-18 07:00AM  XOMA Acquires Royalty Interest Position from Agenus on Seven Assets Being Developed by Merck and Incyte GlobeNewswire
Aug-28-18 07:00AM  XOMA to Present at the H. C. Wainwright 20th Annual Global Investment Conference GlobeNewswire
Aug-09-18 07:00AM  XOMA to Present at the 2018 Wedbush PacGrow Healthcare Conference and the 2018 Southern California Investor Conference GlobeNewswire
Aug-07-18 06:15PM  Xoma (XOMA) Reports Q2 Loss, Lags Revenue Estimates Zacks
05:08PM  Xoma: 2Q Earnings Snapshot Associated Press
04:35PM  XOMA Reports Second Quarter 2018 Financial Results GlobeNewswire
07:40AM  Detailed Research: Economic Perspectives on Alleghany, Enable Midstream Partners, LP, XOMA, MCBC, Unifi, and Tyler Technologies What Drives Growth in Today's Competitive Landscape GlobeNewswire
Jun-26-18 07:00AM  XOMA Added to the Russell 2000® and Russell 3000® Indexes GlobeNewswire
May-15-18 07:00AM  XOMA to Present at the UBS Global Healthcare Conference GlobeNewswire
May-09-18 06:11PM  Xoma: 1Q Earnings Snapshot Associated Press
04:05PM  XOMA Reports First Quarter 2018 Financial Results GlobeNewswire
May-08-18 07:00AM  XOMA Announces $20 Million Credit Facility with Silicon Valley Bank to Advance Royalty-Aggregator Business Model GlobeNewswire
May-02-18 07:30AM  New Research: Key Drivers of Growth for HTG Molecular Diagnostics, Impinj, XOMA, Stock Yards, TriCo Bancshares, and Alleghany Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Apr-03-18 07:00AM  XOMA to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire +5.89%
Mar-20-18 07:35AM  Investor Expectations to Drive Momentum within Key Energy Services, XOMA, Goldman Sachs BDC, Echo Global Logistics, Ellington Residential Mortgage REIT, and Phibro Animal Health Discovering Underlying Factors of Influence GlobeNewswire
Mar-07-18 05:46PM  Xoma reports 4Q loss Associated Press +7.78%
04:05PM  XOMA Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update GlobeNewswire
Mar-05-18 07:00AM  XOMA to Present at the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Feb-19-18 10:04AM  AbbVie Presents New Data on Upadacitinib for Crohn's Disease Zacks
Feb-16-18 09:56AM  FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review Zacks
Feb-14-18 05:48PM  AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda Zacks
Feb-08-18 11:26AM  Theravance, J&J Ink Deal for Inflammatory Intestinal Drug Zacks
09:49AM  Keryx (KERX) Loss Wider Than Expected in Q4, Stock Down Zacks
Feb-06-18 10:00AM  Pfizer Files for Xtandi in Early Stage Prostate Cancer Zacks
Feb-02-18 10:00AM  Puma, CANbridge Team Up to Commercialize Nerlynx in China Zacks
09:30AM  Alnylam's (ALNY) RNAi Candidate's NDA Gets Priority Review Zacks
Jan-31-18 09:17AM  Puma & Medison Team Up to Commercialize Nerlynx in Israel Zacks
Jan-30-18 11:14AM  Theravance's NDA for COPD Candidate Gets FDA Acceptance Zacks
Jan-29-18 10:22AM  Glaxo's Shingles Vaccine Shingrix Gets Positive CHMP Opinion Zacks
Jan-26-18 03:54PM  East Bay drug maker soars 700 percent on Wall Street with plan to NOT make drugs American City Business Journals
Jan-25-18 10:30AM  Dr. Reddy's (RDY) Q3 Earnings Fall, Revenues Improve Y/Y Zacks
10:29AM  Shire Gets FDA Nod for Cinryze Tech Transfer to New Site Zacks
Jan-24-18 03:22PM  EU Unlikely to Approve Puma's Nerlynx in 2018, Stock Down Zacks
Jan-23-18 11:30AM  3 Pharma and Biotech Stocks to Watch Out for in 2018 InvestorPlace
10:45AM  Anthera's Sollpura Strong on Positive Futility in Phase III Zacks
09:42AM  Regeneron's Dupixent Receives MHLW Nod for Label Expansion Zacks
Jan-22-18 10:22AM  Bristol-Myers (BMY) Reports Data from CheckMate-142 Study Zacks
08:43AM  Acorda Therapeutics (ACOR) Jumps: Stock Rises 8.8% Zacks
Jan-17-18 09:36AM  Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It? Zacks
07:35AM  Recent Analysis Shows XOMA, Washington Real Estate Investment Trust, TransMontaigne Partners, Triumph, Hemispherx BioPharma, and Virtus Investment Partners Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jan-15-18 08:15AM  3 Pharma and Biotech Stocks to Watch Out for in 2018 Zacks
Jan-12-18 12:46PM  Aradigm's Bronchiectasis Candidate Has Negative FDA Vote Zacks
10:05AM  Perrigo (PRGO) Hits 52-Week High: What's Driving the Stock? Zacks
Jan-11-18 09:46AM  Vertex's Cystic Fibrosis Drug Ok'd for Pediatric Use in EU Zacks
08:01AM  Why is Novo Nordisk Stock Up More Than 50% in Past Year? Zacks
Jan-10-18 09:00AM  Adamas (ADMS) Launches Dyskinesia Drug in the US, Stock Up Zacks
Jan-09-18 04:35PM  Acorda's Shares Down on Disappointing Ampyra View for 2018 Zacks
09:58AM  Novo Nordisk Confirms Bid for Ablynx But Faces Rejection Zacks
Jan-08-18 03:00PM  It was a banner year for stocks, but not everyone shared in the wealth. American City Business Journals
08:49AM  The Zacks Analyst Blog Highlights: XOMA, Exelixis, Emergent BioSolutions and Medicines Zacks
07:00AM  XOMA Strengthens Leadership Team with Appointments of Chief Business Officer and General Counsel GlobeNewswire
Jan-05-18 04:25PM  4 Biotech Stocks to Watch in the New Year Zacks
09:47AM  Emergent Starts Phase II Study on Anti-influenza Candidate Zacks
Jan-04-18 09:58AM  United Therapeutics (UTHR) Collaborates With Corsair Pharma Zacks -5.63%
09:53AM  Pfizer (PFE) Collaborates With Sangamo for Gene Therapy Zacks
Jan-03-18 01:40PM  Thermo Fisher Buys Phenom-World, Aids Analytical Instruments Zacks
09:41AM  Inovio Amends Chinese Deal for Immunotherapy, Shares Up Zacks
06:34AM  3 Best Healthcare Stocks of 2017 Motley Fool
03:04AM  Anika Therapeutics Receives FDA Nod for Bone Repair Therapy Zacks
Jan-02-18 09:09AM  PetMed Rides on Solid Reorders & New Orders Amid Competition Zacks
Dec-28-17 08:07AM  5 of the Best-Performing Biotech Stocks of 2017 Zacks
Dec-27-17 12:05PM  ETFs with exposure to XOMA Corp. : December 27, 2017 Capital Cube
Dec-20-17 03:44PM  3 Buy-Ranked Biotech Stocks That Soared in 2017 Zacks
02:21PM  Pfizer's Leukemia Drug Gets FDA Nod in First-Line Setting Zacks
07:43AM  Biogen, Ionis Ink Deal for Spinal Muscular Atrophy Therapies Zacks
Dec-19-17 10:30AM  Pfizer Hikes Dividend, Announces $10B Share Buyback Plan Zacks
07:30AM  Free Post Earnings Research Report: XOMAs Revenue Grew 5597.6% ACCESSWIRE
Dec-18-17 08:23AM  Sanofi/Alnylam Say FDA Lifts Clinical Hold on Fitusiran Zacks
Dec-17-17 09:09AM  The 3 Best Biotech Stocks of 2017 Motley Fool
Dec-11-17 02:17PM  ETFs with exposure to XOMA Corp. : December 11, 2017 Capital Cube
07:01AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating XOMA Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
Dec-08-17 08:10AM  Todays Research Reports on Stocks to Watch: Halozyme Therapeutics and Xoma Corporation ACCESSWIRE
XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies. It has research and development collaboration agreements with Novartis Vaccines and Diagnostics, Inc.; Novartis Pharma AG; Novartis International Pharmaceutical Ltd.; Rezolute, Inc.; and Takeda Pharmaceutical Company Limited. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BVF PARTNERS L P/IL10% OwnerMay 14Buy14.7413,816203,664746,454May 14 09:01 PM
BVF PARTNERS L P/IL10% OwnerMay 13Buy14.363,79754,526732,638May 14 09:01 PM
BVF PARTNERS L P/IL10% OwnerMay 10Buy14.5710,300150,037728,841May 14 09:01 PM
VAN NESS W DENMANDirectorMay 10Sale14.711301,9120May 14 06:38 PM
BVF PARTNERS L P/IL10% OwnerDec 17Buy14.1925,000354,793718,541Dec 19 09:26 PM
BVF PARTNERS L P/IL10% OwnerDec 13Buy14.4124,253349,525693,541Dec 13 06:54 PM
BVF PARTNERS L P/IL10% OwnerDec 12Buy14.752,81041,448669,288Dec 13 06:54 PM
BVF PARTNERS L P/IL10% OwnerDec 11Buy14.509,400136,270666,478Dec 13 06:54 PM
BVF PARTNERS L P/IL10% OwnerDec 10Buy14.5418,081262,972657,078Dec 10 07:03 PM
BVF PARTNERS L P/IL10% OwnerDec 07Buy14.7732,015472,778638,997Dec 10 07:03 PM
BVF PARTNERS L P/IL10% OwnerDec 06Buy14.8010,927161,698606,982Dec 10 07:03 PM
BVF PARTNERS L P/IL10% OwnerDec 04Buy14.994,17162,515596,055Dec 04 07:01 PM
BVF PARTNERS L P/IL10% OwnerDec 03Buy14.9080612,009591,884Dec 04 07:01 PM
BVF PARTNERS L P/IL10% OwnerNov 30Buy14.854,82371,615591,078Dec 04 07:01 PM
BVF PARTNERS L P/IL10% OwnerNov 29Buy14.9310,016149,543586,255Nov 29 05:55 PM
BVF PARTNERS L P/IL10% OwnerNov 28Buy15.118,288125,262576,239Nov 29 05:55 PM
BVF PARTNERS L P/IL10% OwnerNov 27Buy15.2411,396173,680567,951Nov 29 05:55 PM
BVF PARTNERS L P/IL10% OwnerNov 21Buy15.0025,000374,893556,555Nov 21 05:42 PM
BVF PARTNERS L P/IL10% OwnerNov 20Buy13.6837,482512,701531,555Nov 21 05:42 PM
BVF PARTNERS L P/IL10% OwnerNov 19Buy13.939,771136,064494,073Nov 21 05:42 PM
BVF PARTNERS L P/IL10% OwnerNov 16Buy13.8210,849149,986484,302Nov 19 10:21 AM
VAN NESS W DENMANDirectorNov 15Option Exercise6.857,69352,69914,672Nov 16 04:31 PM
BVF PARTNERS L P/IL10% OwnerNov 15Buy13.3121,141281,361473,453Nov 19 10:21 AM
VAN NESS W DENMANDirectorNov 15Sale12.675,52870,0409,144Nov 16 04:31 PM
Neal James RCEONov 13Buy13.264,00053,05620,333Nov 15 04:09 PM